New Award: RFA-DK-18-021: Discovery of Early Type 1 Diabetes Disease Biomarkers in the Human Pancreas (CBDS)
One new HIRN CBDS grant was awarded “Development of an Early Diagnostic Biomarker and Novel Treatment Strategy for T1D” to Dr. Anath Shalev at the University of Alabama at Birmingham.
Summary: The objective of this HIRN grant is to establish a non-invasive biomarker for pancreatic beta cell loss in humans with T1D and help develop novel approaches for the early diagnosis and treatment of T1D.
|Anath Shalev, MD
|Shalev Lab Members
|Visual Schematic of Project